New York, USA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Osteosarcoma Pipeline as 30+ Influential Pharma Players to Set Foot in the Domain
The prevalence of Osteosarcoma has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of Osteosarcoma and the rise in research and development activities. The Companies developing the potential therapies in the last stage of development include Lee's Pharmaceutical Limited, Eisai Co Ltd., Jiangsu Hengrui Medicine, and several others.
DelveInsight’s 'Osteosarcoma Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline osteosarcoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the osteosarcoma pipeline domain.
Key Takeaways from the Osteosarcoma Pipeline Report
- DelveInsight’s osteosarcoma pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for osteosarcoma treatment.
- Key osteosarcoma companies such as AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai Co Ltd, Jiangsu Hengrui Medicine, AstraZeneca, Y-mAbs Therapeutics, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., MacroGenics, Shanghai Pharmaceuticals Holding, Celgene, Hutchmed, MedImmune LLC, Lee's Pharmaceutical Limited, EMD Serono, Iovance Biotherapeutics, Inc., BioEclipse Therapeutics, BioAtla, Inc., Celgene, Actuate Therapeutics Inc., and others are evaluating new drugs for Osteosarcoma to improve the treatment landscape.
- Promising osteosarcoma pipeline therapies in various stages of development include ALMB 0168, ZN c3, Arfolitixorin, Lenvatinib, Camrelizumab, Ceralasertib, Humanized anti-GD2 antibody, Targeting CD276 CAR T cells, CLR- 131, Pembrolizumab, Surufatinib, Enoblituzumab, Durvalumab, ZKAB001, M6620, Aldesleukin, CRX100, CAB-AXL-ADC, CC-486, CC-115, 9-ING-41, Palbociclib, and others.
- In September 2022, TheraVet it has entered into an exclusive distribution agreement with Invictos Orthopedics LLC, a North American company designing, developing, and commercializing veterinary orthopedic products and medical devices. Under the terms of the agreement, Invictos will promote and distribute BIOCERA-VET® throughout the United States of America. This distribution agreement covers the full range of BIOCERA-VET® products, i.e., BIOCERA-VET® Bone Surgery RTU, BIOCERA-VET® SmartGraft, BIOCERA-VET® Granules, and BIOCERA-VET® Osteosarcoma RTU.
- In September 2022, OS Therapies and Team Arnav Foundation, a non-profit 501c3 organization focused on finding and funding new research to diagnose and treat pediatric bone and soft tissue tumors, including sarcoma and osteosarcoma - announced their partnership to support the ongoing AOST-2121 COG PhIIb clinical trial in Osteosarcoma.
- In September 2022, The FDA granted an orphan drug designation (ODD) to DUNP19 for the treatment of osteosarcoma, according to an announcement from Radiopharm Theranostics.
- In June 2022, TheraVet announced the commercial launch of its BIOCERA-VET products, including BIOCERA-VET Bone Surgery Ready-to-Use, BIOCERA-VET Granules, and BIOCERA-VET Osteosarcoma Ready-To-Use in the United States of America.BIOCERA-VET synthetic bone substitutes, including BIOCERA-VET Bone Surgery RTU (2 references), BIOCERA-VET Granules (3 references), and BIOCERA-VET Osteosarcoma RTU (2 references), will be available to the US market.
- In April 2022, HebeCell Corporation and Vuja De Sciences, Inc. announced their ongoing R&D collaboration agreement and signed a memorandum of understanding for further development and commercialization of therapies uniquely suited to prevent and treat metastatic cancer recurrence. The companies will focus initially on the orphan disease osteosarcoma (OS).
- In March 2022, SELLAS Life Sciences Group, Inc. and GenFleet Therapeutics announced that the companies have entered into an exclusive license agreement that grants rights to SELLAS for the development and commercialization of GFH009, a highly selective small molecule cyclin-dependent kinase 9 (“CDK9”) inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong Kong, Macau, and Taiwan).
- In January 2022, Cyclenium Pharma, Inc. and Vuja De Sciences, Inc. announced the signing of a drug discovery collaboration agreement. The companies will screen and optimize lead candidates to advance treatments uniquely suited for preventing cancer metastatic recurrence, the biggest unmet need in oncology.
Request a sample and discover the recent advances in osteosarcoma treatment drugs @Osteosarcoma Pipeline Report
The osteosarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage osteosarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the osteosarcoma clinical trial landscape.
Osteosarcoma Overview
Osteosarcoma is a rare form of bone cancer in which cancerous cells produce irregular bone. Although osteosarcoma can affect people of any age, it is most common in children and teenagers who are still growing. The tumor typically develops at the ends of the long bones, particularly around the knee and shoulder, but it can occur anywhere in the body. The exact osteosarcoma causes are unknown. Osteosarcoma can run in families in some cases.
The most common osteosarcoma symptom is pain. This pain may come and go at first, but it will eventually become constant. Some patients may experience swelling or a mass in the tumor’s vicinity. Medical history and physical examination; imaging tests such as X-rays, CT scans, MRIs, bone scans, and PET scans; and biopsy are used for osteosarcoma diagnosis.
Find out more about osteosarcoma guidelines @Osteosarcoma Treatment Guidelines
A snapshot of the Osteosarcoma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| ZKAB001 | Lee's Pharmaceutical Limited | Phase III | Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants | NA |
| Lenvatinib | Eisai Co Ltd/Merck & Co | Phase II | Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists | Oral |
| Camrelizumab | Jiangsu Hengrui Medicine | Phase II | Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants | NA |
| ZN c3 | Zentalis Pharmaceuticals | Phase I/II | WEE1 protein inhibitors | Oral |
| ALMB 0168 | AlaMab Therapeutics | Phase I/II | Connexin 43 stimulants | Intravenous |
Learn more about the emerging Osteosarcoma pipeline therapies @Osteosarcoma Clinical Trials
Osteosarcoma Therapeutics Assessment
The osteosarcoma pipeline report proffers an integral view of osteosarcoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Osteosarcoma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
- Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
- Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Programmed cell death-1 ligand-1 inhibitors, T lymphocyte stimulants, Platelet derived growth factor alpha receptor antagonists, Proto oncogene protein c ret inhibitors, Proto oncogene protein c-kit inhibitors, Type 1 fibroblast growth factor receptor antagonists, Type 3 fibroblast growth factor receptor antagonists, Type 4 fibroblast growth factor receptor antagonists,Type-2 fibroblast growth factor receptor antagonists, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists, WEE1 protein inhibitors, Connexin 43 stimulants, ERBB 2 receptor antagonists; Immunostimulants
- Key Osteosarcoma Companies:AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai Co Ltd, Jiangsu Hengrui Medicine, AstraZeneca, Y-mAbs Therapeutics, Innovent Biologics, PersonGen BioTherapeutics (Suzhou), Cellectar Biosciences, Inc., MacroGenics, Shanghai Pharmaceuticals Holding, Celgene, Hutchmed, MedImmune LLC, Lee's Pharmaceutical Limited, EMD Serono, Iovance Biotherapeutics, Inc., BioEclipse Therapeutics,BioAtla, Inc., Celgene, Actuate Therapeutics Inc. and others
- Key Osteosarcoma Pipeline Therapies: ALMB 0168, ZN c3, Arfolitixorin, Lenvatinib, Camrelizumab, Ceralasertib, Humanized anti-GD2 antibody, Targeting CD276 CAR T cells, CLR- 131, Pembrolizumab, Surufatinib, Enoblituzumab, Durvalumab, ZKAB001, M6620,Aldesleukin, CRX100, CAB-AXL-ADC,CC-486, CC-115, 9-ING-41,Palbociclib and others
Dive deep into rich insights for new drugs for osteosarcoma treatment, visit @Osteosarcoma Medications
Table of Contents
| 1. | Osteosarcoma Pipeline Report Introduction |
| 2. | Osteosarcoma Pipeline Report Executive Summary |
| 3. | Osteosarcoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Osteosarcoma Clinical Trial Therapeutics |
| 6. | Osteosarcoma Pipeline: Late Stage Products (Pre-registration) |
| 7. | Osteosarcoma Pipeline: Late Stage Products (Phase III) |
| 7.1 | ZKAB001: Lee's Pharmaceutical Limited |
| 8. | Osteosarcoma Pipeline: Mid Stage Products (Phase II) |
| 8.1 | Camrelizumab: Jiangsu Hengrui Medicine |
| 9. | Osteosarcoma Pipeline: Early Stage Products (Phase I) |
| 10. | Osteosarcoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Osteosarcoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Osteosarcoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the osteosarcoma pipeline therapeutics, reach out @Osteosarcoma Treatment Drugs
Related Reports
Osteosarcoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteosarcoma companies including Y-mAbs Therapeutics, Jiangsu Hengrui Medicine, AstraZeneca, Advenchen Laboratories LLC, among others.
Osteosarcoma Epidemiology Forecast
Osteosarcoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted osteosarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Ewing Sarcoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ewing sarcoma companies, including Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, among others.
Soft Tissue Sarcoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key soft tissue sarcoma companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, among others.
Clear Cell Sarcoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key clear cell sarcoma companies, including Tesaro, NantPharma, Rafael Pharmaceuticals, Pfizer, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
Related Healthcare Blogs
Osteosarcoma vs. Ewing Sarcoma
Ewing Sarcoma Market Landscape
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
